Peptide library / AOD-9604

AOD-9604

AOD-9604 is a modified peptide fragment derived from the C-terminal region of human growth hormone; it is distinct from full-length somatropin.

Peptide & blend guide

The short version

Why people discuss it
Discussed for fat loss and body composition, despite unresolved clinical efficacy. Community interest does not establish benefit or a suitable treatment.
What it is
AOD-9604 is a modified peptide fragment derived from the C-terminal region of human growth hormone; it is distinct from full-length somatropin.
Biggest caution
Evidence for a fragment cannot be substituted for somatropin evidence, and neither establishes a community weight-loss protocol. Product identity and long-term safety require separate evaluation.
Stack context
Related profiles reflect adjacent community topics or biological context. They do not establish combination benefit, compatibility or a validated regimen.

Dose and frequency reference

Reference only — not a recommendation. Amounts describe source-specific community examples, selected study regimens or the named product label. They do not establish safety, effectiveness, product identity, or a suitable dose for any person. Never convert mg, mcg, or IU into syringe “units” without the exact product concentration.

Source agreement describes reported practice, not clinical validation.

Subcutaneous injection

Community reference · Not clinical guidance
Amount
300–500 mcg
Frequency
Once daily
Duration / phase
8–12 weeks; one source describes 4–8 weeks off

Both new sources describe 300 mcg as a starting amount and 500 mcg as a higher reported amount. Oral clinical studies do not validate these subcutaneous community regimens. Reference only; this does not establish safety, effectiveness or individual suitability.

Community source · reviewed 2026-09-27
Compare reported schedules

Saved source material reviewed 2026-09-27. Multiple pages from one publisher count as one source family; agreement does not establish what most people use. SC means subcutaneous; IM intramuscular; IP intraperitoneal.

Evidence & sources · Community source profile

AxonRep synthesizes community discussion signals from its internal research corpus. Individual creator sources remain attributed to the synthesis; public reference sites used in the latest comparison are linked separately. The synthesis is not clinical evidence.

Back to the peptide library